FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart A

This expansion applies to the estimated 70 million patients who need either primary or secondary prevention, regardless of statin use.

Related Keywords

Sheldon Koenig , European Medicines Agency , Committee For Medicinal Products Human , Esperion Therapeutic , Olivier Le Moal , Medicinal Products , Cardiovascular , Heart Attack , Fda Approval , Nexletol , Nexlizet ,